Stifel downgraded Vigil Neuroscience (VIGL) to Hold from Buy with a price target of $8, down from $11, following the proposed all-cash transaction by Sanofi (SNY) for $8 per share. Individuals representing 16.2% of Vigil’s total common shares outstanding have already signed voting and support agreements in favor of the deal, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIGL:
- Hold Rating on Vigil Neuroscience Amid Sanofi Acquisition and VG-3927 Developments
- Vigil Neuroscience downgraded to Neutral from Buy at H.C. Wainwright
- Vigil Neuroscience Elects Directors at Annual Meeting
- Vigil Neuroscience downgraded to Neutral from Outperform at Mizuho
- Vigil Neuroscience downgraded to Hold from Buy at Jefferies